{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:53:41Z","timestamp":1787025221430,"version":"build-2736575974"},"reference-count":28,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Off-label prescription in paediatric patients is common, where some studies indicate that dermatological conditions are more prone to off-label treatment. This is the first study to analyse the prevalence of off-label prescription in paediatric dermatology consultation. This retrospective observational study was performed using the medical records of paediatric patients who were evaluated in a paediatric dermatological consultation in Pontevedra University Hospital, Pontevedra, Spain. Of the 468 patients reviewed, 186 prescriptions were issued and 51.10% were off-label prescription drugs. The dermatological conditions for which off-label prescription was most common were atopic dermatitis (29.0%), followed by warts (12.9%) and infantile haemangiomas (11.8%). With respect to drugs, topical tacrolimus (23.7%) was the most frequently prescribed off-label drug. The main reason for prescribing an off-label drug was for a disease not included on the label (62.4%), followed by issuing it at a lower age than authorized (55.9%). There was a significant association between a higher percentage of off-label prescription and younger age (p\u2009&lt;\u20090.001), and the treatment of vitiligo, infantile haemangiomas and warts (p\u2009&lt;\u20090.001). Likewise, the off-label prescription was significantly more common in the case of topical terbinafine, timolol, desloratadine and topical salicylic acid (p\u2009&lt;\u20090.001). To conclude, off-label prescription is predominant in paediatric dermatology, as observed in 51.1% of our patients.<\/jats:p>","DOI":"10.2340\/actadv.v102.11937","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T08:30:26Z","timestamp":1702283426000},"page":"adv11937","source":"Crossref","is-referenced-by-count":5,"title":["Off-label Prescription in Paediatric Dermatology: A Retrospective Observational Study in a Tertiary Hospital"],"prefix":"10.2340","volume":"103","author":[{"given":"Carmen","family":"Couselo-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"D\u00e1vila-Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Soto-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Vilanova-Trillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"43419","doi-asserted-by":"crossref","unstructured":"Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol 2015; 79: 357-369.","DOI":"10.1111\/bcp.12305"},{"key":"43420","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bcp.12305","DOI":"10.1111\/bcp.12305"},{"key":"43421","doi-asserted-by":"crossref","unstructured":"Lass J, Irs A, Pisarev H, Leinemann T, Lusar I. Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf 2011; 20: 474-481.","DOI":"10.1002\/pds.2125"},{"key":"43422","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/pds.2125","DOI":"10.1002\/pds.2125"},{"key":"43423","doi-asserted-by":"crossref","unstructured":"Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L et al. Pediatric off-label drug use in China: risk factor and management strategies. J Evid Based Med 2013; 6: 4-18.","DOI":"10.1111\/jebm.12017"},{"key":"43424","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jebm.12017","DOI":"10.1111\/jebm.12017"},{"key":"43425","doi-asserted-by":"crossref","unstructured":"Schirm E, Tobi H, de Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003; 111: 291-295.","DOI":"10.1542\/peds.111.2.291"},{"key":"43426","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1542\/peds.111.2.291","DOI":"10.1542\/peds.111.2.291"},{"key":"43427","doi-asserted-by":"crossref","unstructured":"Parikh SA, David SA, Krowchuk DP, Feldman SR. Common use of prescription off-label acne therapy in children younger than 12 years old. Pediatr Dermatol 2014; 31: 551-555.","DOI":"10.1111\/pde.12379"},{"key":"43428","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.12379","DOI":"10.1111\/pde.12379"},{"key":"43429","doi-asserted-by":"crossref","unstructured":"Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87: 982-990.","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"43430","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.04.017","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"43431","doi-asserted-by":"crossref","unstructured":"Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie 2018; 73: 135-149.","DOI":"10.1016\/j.therap.2018.02.002"},{"key":"43432","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.therap.2018.02.002","DOI":"10.1016\/j.therap.2018.02.002"},{"key":"43433","doi-asserted-by":"crossref","unstructured":"Gerlero P, Hern\u00e1ndez-Mart\u00edn \u00c1. Treatment of warts in children: an update. Actas Dermosifiliogr 2016; 107: 551-558.","DOI":"10.1016\/j.adengl.2016.06.001"},{"key":"43434","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2016.04.010","DOI":"10.1016\/j.ad.2016.04.010"},{"key":"43435","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Garza FZ, R\u00edos M, Ro\u00e9-Crespo E, Bernabeu-Wittel J, Montesarrat-Garc\u00eda MT, Puig L et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage. JAMA Dermatol 2021; 157: 583-587.","DOI":"10.1001\/jamadermatol.2021.0596"},{"key":"43436","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.0596","DOI":"10.1001\/jamadermatol.2021.0596"},{"key":"43437","doi-asserted-by":"crossref","unstructured":"Roohaninasab M, Mansouri P, Seirafianpour F, Naeini AJ, Goodarzi A. Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: a comprehensive review study. Dermatol Ther 2021; 34: e14550.","DOI":"10.1111\/dth.14550"},{"key":"43438","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14550","DOI":"10.1111\/dth.14550"},{"key":"43439","doi-asserted-by":"crossref","unstructured":"Mah\u00e9 E, Corgibet F, Maccari F, Hadj-Rabia S, Phan C, Ruer-Mulard M et al. Off-label drugs in childhood psoriasis. Ann Dermatol Venereol 2020; 147: 429-438.","DOI":"10.1016\/j.annder.2020.01.021"},{"key":"43440","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annder.2020.01.021","DOI":"10.1016\/j.annder.2020.01.021"},{"key":"43441","doi-asserted-by":"crossref","unstructured":"Blanco-Reina E, Vega-Jim\u00e9nez MA, Oca\u00f1a-Riola R, M\u00e1rquez-Romero EI, Bellido-Est\u00e9vez I. Drug prescriptions study in the outpatient setting: assessment of off-label uses in children. Aten Primaria 2015; 47: 344-350.","DOI":"10.1016\/j.aprim.2014.07.010"},{"key":"43442","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.aprim.2014.07.010","DOI":"10.1016\/j.aprim.2014.07.010"},{"key":"43443","doi-asserted-by":"crossref","unstructured":"Ellul IC, Grech V, Attard-Montalto S. Paediatric off-label and unlicensed prescribing in primary care in Malta: prospective observational drug utilisation study. Int J Risk Saf Med 2015; 27: 123-134.","DOI":"10.3233\/JRS-150654"},{"key":"43444","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3233\/JRS-150654","DOI":"10.3233\/JRS-150654"},{"key":"43445","doi-asserted-by":"crossref","unstructured":"Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009; 9: 81-88.","DOI":"10.1016\/j.acap.2008.11.010"},{"key":"43446","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.acap.2008.11.010","DOI":"10.1016\/j.acap.2008.11.010"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/11937\/39783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/11937\/39783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T08:31:12Z","timestamp":1702283472000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/11937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.11937","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}